Evaluation of the efficacy and safety of etoricoxib in the treatment of hemophilic arthropathy
Open Access
- 1 March 2006
- journal article
- research article
- Published by American Society of Hematology in Blood
- Vol. 107 (5), 1785-1790
- https://doi.org/10.1182/blood-2004-09-3501
Abstract
This 2-part, double-blind, placebo-controlled study was conducted to determine the safety and efficacy of etoricoxib, a COX-2 selective inhibitor, for the treatment of hemophilic arthropathy. In part 1 (6 weeks), 102 patients (≥ 12 years old) with hemophilic arthropathy were randomized to receive 90 mg etoricoxib once daily or placebo (1:1 ratio). In part 2 (6 months), 51 patients taking placebo in part 1 were randomized to receive 90 mg etoricoxib or 25 mg rofecoxib once daily; patients taking etoricoxib in part 1 continued the same treatment. Efficacy end points included Patient Assessment of Arthropathy Pain, Patient Global Assessment of Arthropathy Disease Status, and Investigator Global Assessment of Arthropathy Disease Status. Safety was evaluated at each study visit. Etoricoxib provided significant improvement in all end points versus placebo (P < .001). Fewer patients taking etoricoxib discontinued due to a lack of efficacy versus placebo (P = .048). During part 2, efficacy was maintained; etoricoxib and rofecoxib demonstrated similar results. The most common adverse experiences were upper respiratory infection and headache. The incidence of joint bleeding during part 1 was similar between etoricoxib (66.7%) and placebo (72.6%) and during part 2 between etoricoxib (77.0%) and rofecoxib (78.9%). We conclude that etoricoxib provided superior efficacy versus placebo for the treatment of hemophilic arthropathy and was generally safe and well tolerated.Keywords
This publication has 26 references indexed in Scilit:
- A randomized, double‐blind clinical trial of two doses of meloxicam compared with naproxen in children with juvenile idiopathic arthritis: Short‐ and long‐term efficacy and safety resultsArthritis & Rheumatism, 2005
- EtoricoxibDrugs of Today, 2004
- Blood-Induced Joint Damage in HemophiliaSeminars in Thrombosis and Hemostasis, 2003
- Serious lower gastrointestinal clinical events with nonselective NSAID or coxib useGastroenterology, 2003
- The Hemophilias — From Royal Genes to Gene TherapyNew England Journal of Medicine, 2001
- Renal Effects of COX-2-Selective InhibitorsAmerican Journal of Nephrology, 2001
- Opioid AnalgesicsDrugs, 1996
- Gastrointestinal bleeding in hemophilia as a complication of the use of over the counter non-steroidal anti-inflammatory drugsAmerican Journal of Hematology, 1994
- Quantitation of thermography in arthritis using multi-isothermal analysis. II. Effect of nonsteroidal anti-inflammatory therapy on the thermographic index.Annals Of The Rheumatic Diseases, 1974
- Clinical measurement of the anti-inflammatory effects of salicylates in rheumatoid arthritis.BMJ, 1967